The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|November 2, 2015
- Pharmaceutical Technology-11-02-2015
- Volume 39
- Issue 11
Pharmaceutical Technology, November 2015 Issue (PDF)
Click the title above to open the Pharmaceutical Technology November 2015 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 11 years ago
Using Dynamic Thermal Imaging to Correct Sealing Problemsalmost 11 years ago
CMOs Continue to Improve Overall Biomanufacturing Performancealmost 11 years ago
FDA Overhauls Inspection Operationsalmost 11 years ago
Good Documentation Practice: Saving Data for the Long Termalmost 11 years ago
Identifying Causes Of Delaminationalmost 11 years ago
Piloting Track-and-Trace Implementationalmost 11 years ago
Advances in Heterocyclic Chemistry for API Synthesisalmost 11 years ago
EU’s New Telematics Strategy for the Regulation of Medicinesalmost 11 years ago
Exploring the Potential of Continuous Coatingalmost 11 years ago
Demonstrating Therapeutic Equivalence for Generic Topical ProductsAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement